INTRODUCTION {#S2}
============

Uveal melanomas (UMs) arise from the melanocytes of the eye. While localized disease can be effectively treated surgically, half of all patients develop metastasis, and metastatic UM carries a dismal prognosis with an overall survival of only 6 months ([@R14]). Approximately half of the patients harbor metastases to multiple organs, with liver (93%), lung (24%), bone (16%), and lymph nodes (10%) representing the most common sites ([@R11]). Over the past decade, we have gained considerable insight into the genetic basis of UM. This has not yet led to novel therapeutic options and there are still no proven systemic treatments for UM.

UM is highly distinct from cutaneous melanoma (CM) both clinically and molecularly. UM is not associated with sun exposure and has among the lowest mutation rates in cancer, whereas CM has among the highest mutation rates due to UV damage ([@R17]). A recent comparison of liver metastasis revealed that most CM metastases lacked gross melanin pigmentation while most UM metastases are hyperpigmented and express high levels of melanocyte lineage proteins, such as MART-1 (*MLANA*) and gp100 (*PMEL*) ([@R39]). Molecularly, CM is driven by recurrent somatic mutations that activate the mitogen-activated protein kinase (MAPK) pathway, including *BRAF*, *NRAS*, *NF1*, and *KIT*. Approximately 90% of UMs harbor activating mutations in two homologous G-protein alpha (Gα) subunits, *GNA11* (Gα~11~) and *GNAQ* (Gα~q~), at codons Gln209 or Arg183 ([@R38]; [@R43], 2010). Among the remaining 10% of UMs, most harbor activating mutations in a G-protein-coupled receptor (*CYSLTR2* at the Leu129 codon activates Gα~11/q~) or in phospholipase C β4 (*PLCB4*) (at the Asp630 codon, a direct downstream effector of Gα~11/q~ cleaves phosphatidylinositol 4,5-bisphosphate \[PIP~2~\] to produce the second messengers diacylglycerol \[DAG\] and inositol triphosphate \[IP~3~\] ([@R26]; [@R35]). This indicates a requirement for Gα~11/q~-coupled signaling and, in particular, the phospholipase Cβ (PLCβ) effector pathway in the initiation of UMs.

While essentially all UMs harbor mutations in the CYSLTR2-Gα~11/q~-PLCβ pathway, the prognosis is largely determined by the presence of cooperative mutations. Monosomy 3 and an associated poor-prognosis gene expression pattern is the single most negative prognostic factor. Most of these tumors harbor inactivating mutations in *BAP1*, located at 3q21, and essentially all of these tumors lose expression of the BAP1 protein, implicating BAP1 loss as a critical cooperating lesion driving poor prognosis in UM ([@R22]; [@R38]). Among tumors with disomy 3, there are mutually exclusive mutations in *SF3B1*, associated with intermediate prognosis, and in *EIF1AX*, associated with favorable prognosis ([@R33]; [@R38]).

In addition to UM, CYSLTR2-Gα~11/q~-PLCβ pathway mutations are found in most leptomeningeal melanocytic neoplasms (LMNs) and blue nevi ([@R34]; [@R43]). LMNs are rare neoplasms arising from melanocytes of the leptomeninges. Like UM, in addition to mutations in *GNA11* and *GNAQ*, LMNs harbor mutually exclusive co-mutations in either *EIF1AX* or *SF3B1* in 33% of cases ([@R30]). Blue nevi are common benign neoplasms of dermal melanocytes, which are distinguished from CMs that arise from epidermal melanocytes. Rare malignant melanomas that either arise from blue nevi or show morphologic features of blue nevi are called malignant blue nevi. Recent genetic characterization of a large cohort of blue nevi showed both benign and malignant blue nevi harbored CYSLTR2-Gα~11/q~-PLCβ pathway mutations ([@R34]). *EIF1AX* mutations are found only in benign blue nevi, while *SF3B1* and *BAP1* mutations are found only in malignant blue nevi ([@R21]). Therefore, UM, LMN, and blue nevi represent a molecularly similar spectrum of diseases that commonly harbor CYSLTR2-Gα~11/q~-PLCβ mutations and whose disease aggressiveness is defined by co-mutations, especially *BAP1.*

Because the PLCβ pathway is known to activate MAPK, the MEK inhibitor selumetinib has been clinically studied. While a phase 2 trial showed promising improvement in progression-free survival, the phase 3 trial failed to confirm the finding and neither trial showed an improvement in overall survival ([@R8]; [@R29]). As different MEK inhibitors have distinct properties ([@R32]), it is still currently unclear whether the MAPK pathway remains a viable therapeutic target in UM.

To identify molecular and lineage events downstream of Gα~11~ activation, the cooperative role of BAP1 loss, and critical nodes required for Gα~11~-mediated tumorigenesis, we generated a conditional Rosa26-LSL-GNA11^Q209L^ mouse model and crossed it with conditional Bap1 knockout (KO) mice. These mice recapitulate the features of human Gα~11~-driven melanomas. They developed neoplastic hyperpigmented melanocytic lesions in the uveal tract, skin, and leptomeninges. These mice developed lesions in the lung and lymph nodes. Deletion of *Bap1* accelerated skin tumor growth and mouse mortality. The GNA11^Q209L^, Bap1 loss tumors were resistant to the MEK inhibitor trametinib. To identify alternative therapeutic targets, we performed integrative analysis comparing BRAF mutant and Gα~11/q~ mutant human and murine cancers, and we identified a critical requirement of a Ras guanine exchange factor (GEF), RasGRP3, for Gα~11/q~-mediated tumorigenesis.

RESULTS {#S3}
=======

Melanocyte-Specific *GNA11^Q209L^* Expression Induces Skin, Uveal, and CNS Neoplasia {#S4}
------------------------------------------------------------------------------------

To express *GNA11^Q209L^* in the melanocyte lineage, we generated a genetically engineered mouse model (GEMM) with a conditional *GNA11^Q209L^* allele (*R26*-*LSL-GNA11^Q209L^*) under the control of the endogenous *Rosa26* promoter ([Figures S1A and S1B](#SD1){ref-type="supplementary-material"}). To identify an active Cre-driver for uveal melanocytes, we crossed *Tyr*-*CreER^T2^* transgenic mice that express tamoxifen-inducible CreER^T2^ under the melanocyte-specific *Tyrosinase* (*Tyr*) promoter with the CAG-LSL-EYFP reporter. One week after tamoxifen injection, there was robust EYFP expression in both uveal and skin (hair follicle) melanocytes ([Figure S1C](#SD1){ref-type="supplementary-material"}). We thus generated *Tyr*-*CreER^T2^;GNA11^Q209L^* mice for our studies.

To activate *GNA11^Q209L^* expression, we treated 4-week-old mice with a single application of tamoxifen or vehicle by intraperitoneal injection. In tamoxifen-injected, but not vehicle-injected, mice, we observed hyperpigmentation of ears and tail within 2 weeks of treatment and bulging eyes within 1 month of treatment ([Figure S2A](#SD1){ref-type="supplementary-material"}). In vehicle-treated *Tyr*-*CreER^T2^*-positive or tamoxifen-treated *Tyr*-*CreER^T2^*-negative control mice, there was no discernible pathologic phenotype in the skin or the uveal tract up to 18 months ([Figures 1A, 1B](#F1){ref-type="fig"}, [S2B, and S2C](#SD1){ref-type="supplementary-material"}). In *Tyr*-*CreER^T2^;GNA11^Q209L^* mice, pathological analysis of the skin 3 months post-induction showed extensive follicular and dermal melanocytic proliferation ([Figure 1C](#F1){ref-type="fig"}), which progressed to melanomas encompassing the dermis and subcutaneous tissues in 50% of mice by 6 months after injection ([Figure 1D](#F1){ref-type="fig"}). These proliferating melanocytes stained positive for a melanocyte cocktail ([Figure S2D](#SD1){ref-type="supplementary-material"}). Tumor cells contained abundant pale amphophilic cytoplasm and a small nuclear-to-cytoplasmic ratio ([Figure S2D](#SD1){ref-type="supplementary-material"}). For comparison, we also treated *Tyr*-*CreER^T2^;BRaf^CA/+^* mice, which express the conditional *BRaf^V600E^* allele in melanocytes. We observed melanocytic hyperplasia without progression to melanoma up to 12 months post-induction, similar to previous observations ([Figure S2E](#SD1){ref-type="supplementary-material"}) ([@R12]).

We next examined the oncogenic role of GNA11^Q209L^ and BRaf^V600E^ expression in uveal melanocytes. Within the uveal tract, tamoxifen-injected *Tyr-CreER^T2^;GNA11^Q209L^* mice displayed diffuse hyperplasia, thickening of the choroid and ciliary body that progressed over time to overt UM with intraocular infiltration that distorted the normal architecture of the globe ([Figures 1E and 1F](#F1){ref-type="fig"}). Uveal melanocyte proliferation was evident in mice as early 1 month post-tamoxifen (data not shown). In contrast, the uveal tracts of induced *Tyr-CreER^T2^;BRaf^CA/+^* mice were indistinguishable from those of control mice ([Figures S2F and S2G](#SD1){ref-type="supplementary-material"}). Further examination revealed tumor cells with pathological characteristics similar to skin melanoma ([Figure 1G, i and ii](#F1){ref-type="fig"}). These cells were positive for MITF and melanocyte cocktail staining ([Figure 1G, iii and iv](#F1){ref-type="fig"}). We further observed perineural spread of malignant melanoma to the optic nerve ([Figure 1H](#F1){ref-type="fig"}).

We next examined the effect of *GNA11^Q209L^* in resident melanocytes of other organs, including the heart, harderian gland, and brain ([@R4]). Gross examination of the brain revealed focal pigmentation of the leptomeninges in 80% of mice ([Figure S3A](#SD1){ref-type="supplementary-material"}). Pathological evaluation of the CNS of the *Tyr-CreER^T2^;GNA11^Q209L^* mice showed melanocytic proliferation in the leptomeninges at the base of the brain, around cranial nerve roots, and within the longitudinal fissure ([Figure 2A, ii--iv](#F2){ref-type="fig"}). There was prominent melanocytic hyperplasia within the third ventricle ([Figure 2A, i and iv](#F2){ref-type="fig"}). Clinically, primary melanocytomas occasionally occur within the ventricular system of the CNS ([@R42]). There was invasion of melanocytes to the periventricular space, and one mouse exhibited invasion to the olfactory bulb ([Figure 2A, iv and v](#F2){ref-type="fig"}). We observed robust proliferation of resident melanocytes in the harderian gland ([Figure 2A](#F2){ref-type="fig"}, arrow).

Examining the melanocytes of the heart in GNA11^Q209L^ mice, we observed invasive neoplasms that infiltrated and thickened the tricuspid valve and infiltrated the myocardium of the right atrium and interventricular septum ([Figures 2B and 2C](#F2){ref-type="fig"}). We suspect these lesions were primary tumors of the resident melanocytes of the heart. Melanocytic lesions were not evident in *Tyr-CreER^T2^;BRaf^CA/+^* mice in these areas ([Figures S3C and S3D](#SD1){ref-type="supplementary-material"}).

In GNA11^Q209L^ mice, we observed multi-focal lesions in the lungs that may represent metastases, although we cannot rule out transformation of rare resident lung melanocytes ([Figures 2B, 2D, and 2E](#F2){ref-type="fig"}). However, the morphology of these lesions resembled the primary tumors ([Figures 1D, 1G, ii](#F1){ref-type="fig"}, [2B, and 2C](#F2){ref-type="fig"}). These lesions occurred early and were observed in mice with less advanced skin and uveal lesions ([Figure S3E](#SD1){ref-type="supplementary-material"}). We observed melanocytes infiltrating the lymphatic system, as visualized by MITF staining in the axillary lymph nodes ([Figures 2F and 2G](#F2){ref-type="fig"}). In contrast, we did not observe melanocytic lesions in the CNS, heart, lungs, or lymph nodes in *Tyr-CreER^T2^;BRaf^CA/+^* mice ([Figures S3B--S3D](#SD1){ref-type="supplementary-material"}). Our data are consistent with the clinical absence of *BRAF* mutations in UMs and LMNs and the sporadic occurrence of *GNAQ/11* mutations in CMs.

Recently, a mouse model harboring GNAQ^Q209L^ was characterized ([@R23]). When activated in melanoblasts during embryogenesis with *Mitf*-*Cre*, the mice exhibited UM, LMN, neoplastic melanocytic growth in the harderian glands, and rare lesions in the skin, as well as lymph nodes and lung ([@R23]). When activated in 8-week-old adult mice using *Tyr*-*CreER^T2^*, GNAQ^Q209L^ drove melanocyte overgrowth without progression to melanoma. The phenotype of our *Tyr*-*CreER^T2^; GNA11^Q209L^* mouse model, activated at 4 weeks, appears to be an intermediate between *Mitf*-*Cre* activated before birth and *Tyr*-*CreER^T2^* activated at 8 weeks. The *Mitf*-*Cre;GNAQ^Q209L^* mice developed earlier invasive UM and more diffuse LMN, likely due to earlier expression at mid-gestation and prolonged Cre activation ([@R2]).

Loss of *Bap1* Accelerates Skin Melanomas in the Presence of GNA11^Q209L^ {#S5}
-------------------------------------------------------------------------

We sought to examine the combinatorial effect of GNA11^Q209L^ and the loss of the tumor suppressor Bap1 in the development of UM. To achieve *Bap1* deletion, we crossed *Bap1^lox/lox^* mice ([@R31]) to the *Tyr-CreER^T2^;GNA11^Q209L^* line. Tamoxifen-treated *Tyr-CreER^T2^;Bap1^KO^* mice had no discernible phenotype and were histologically normal over \~20 months, indicating Bap1 loss alone was insufficient to initiate melanoma (n = 35; [Figures S4A and S4B](#SD1){ref-type="supplementary-material"}).

We compared the *Tyr-CreER^T2^;GNA11^Q209L^;Bap1^lox/lox^* mice to the *Tyr-CreER^T2^;GNA11^Q209L^* mice. We observed a stronger ocular phenotype in *GNA11^Q209L^* than *GNA11^Q209L^ Bap1^KO^* mice ([Figures 3A--3C](#F3){ref-type="fig"}). However, the *GNA11^Q209L^ Bap1^KO^* mice succumbed to disease at an accelerated rate compared to *GNA11^Q209L^* or *GNA11^Q209L^ Bap1^lox/+^* mice ([Figure 3D](#F3){ref-type="fig"}; p \< 0.05), due to increased skin melanoma burden ([Figures 3E and 3F](#F3){ref-type="fig"}). The loss of Bap1 in these mice did not appreciably alter the size or incidence of uveal lesions, but it contributed to an increased progression to skin melanomas originating from the tail and ears ([Figures 3E--3G](#F3){ref-type="fig"}). We confirmed Bap1 KO in uveal melanocytes using PCR ([Figure S4C](#SD1){ref-type="supplementary-material"}). Unlike in human UM patients, no pigmented liver lesions were observed ([Figures S4D and S4E](#SD1){ref-type="supplementary-material"}). We observed no significant increase in the size or incidence of lung lesions in the absence of Bap1 ([Figures S3E and S4F--S4H](#SD1){ref-type="supplementary-material"}). Histologically, GNA11^Q209L^ skin melanomas exhibited slender oval nuclei while GNA11^Q209L^;Bap1^KO^ had larger euchromatic nuclei ([Figure 3H](#F3){ref-type="fig"}). GNA11^Q209L^;Bap1^KO^ skin melanomas exhibited a higher proliferation index ([Figures 3H and 3I](#F3){ref-type="fig"}; p \< 0.0001).

To determine the extent that Bap1 KO molecularly recapitulates human melanoma and to understand the Bap1-regulated transcriptional programs, we performed transcriptome analysis of mouse and human melanomas. RNA sequencing (RNA-seq) revealed the *R26-GNA11^Q209L^* transcript level was 4- to 8-fold lower than endogenous murine *Gnaq* and *Gna11* transcript levels, indicating modest expression of mutant *GNA11* is required for tumorigenesis ([Figure S5A](#SD1){ref-type="supplementary-material"}). Analysis of RNA-seq of GNA11^Q209L^ and GNA11^Q209L^;Bap1^KO^ skin melanomas confirmed deletion of *Bap1* ([Figure S5B](#SD1){ref-type="supplementary-material"}). Using a gene set comprised of genes upregulated in GNA11^Q209L^;Bap1^KO^ versus GNA11^Q209L^ skin melanomas (Mouse_Bap1KO_UP), we performed gene set enrichment analysis (GSEA) using The Cancer Genome Atlas (TCGA) UM dataset ([@R38]). This showed Mouse_Bap1KO_UP genes are significantly enriched among genes negatively correlated with *BAP1* expression in UM, suggesting BAP1 deletion in skin melanomas of mice results in the upregulation of similar genes to human UM ([Figure 3J](#F3){ref-type="fig"}; [Table S1](#SD2){ref-type="supplementary-material"}). To explore the function of the shared genes, we performed functional annotation of the leading edge genes ([Figure 3J](#F3){ref-type="fig"}, red) that drove the GSEA enrichment. We found the most enriched gene ontology (GO) and Swiss-Prot (SP) pathways all involved cell cycle and mitosis ([Figure 3K](#F3){ref-type="fig"}).

In a complementary approach, we identified a UM primary tumor line, UPMM3, contained a frameshift deletion of *BAP1* ([Figure S5C](#SD1){ref-type="supplementary-material"}) ([@R20]). We restored wild-type BAP1 ([Figure S5D](#SD1){ref-type="supplementary-material"}) and generated a gene expression profile using RNA-seq. As controls, we expressed BAP1 with mutations in the deubiquitinase domain (p.Cys91Trp, p.Ala95Pro) found in cancer ([@R22]) as well as EGFP. Wild-type BAP1 restoration significantly changed gene expression while the presumably non-functional mutants did not, observed by gene hierarchical clustering ([Figure S5E](#SD1){ref-type="supplementary-material"}). We next performed GSEA, and we found the Mouse_Bap1KO_UP gene set was significantly enriched among genes downregulated in UPMM3 cells by BAP1 (wild-type \[WT\]) restoration ([Figure 3L](#F3){ref-type="fig"}). Functional analysis of leading edge genes showed cell cycle pathways were enriched ([Figure 3M](#F3){ref-type="fig"}). GSEA on three BAP1 datasets (mouse model, TCGA, and UPMM3) using the \>8,300 gene sets from the Molecular Signatures Database (MSigDB) showed cell cycle and melanoma metastasis signatures are highly enriched in each ([Table S1](#SD2){ref-type="supplementary-material"}; [Figures S5F and S5G](#SD1){ref-type="supplementary-material"}). Therefore, in UM, the loss of Bap1 can promote aggressive disease with a propensity to proliferate and metastasize, consistent with clinical data implicating BAP1 loss as a poor prognostic biomarker.

Gα~11/q~-Driven Cells Have Reduced Sensitivity to MEK Inhibition {#S6}
----------------------------------------------------------------

Activation of the Gα~11/q~-PLCβ pathway leads to downstream activation of the MAPK pathway. While preclinical data using UM cell lines suggest MEK inhibition may be a therapeutic strategy ([@R3]), a recent phase 3 study comparing selumetinib and chemotherapy failed to show significant improvement in progression-free or overall survival ([@R29]). Prolonged selumetinib treatment induces RAF-MEK dimer formation, leading to reactivation of MAPK signaling, particularly in non-BRAF^V600E^-driven tumors. The newer MEK inhibitor trametinib uniquely decreases RAF-MEK interaction and MAPK reactivation ([@R32]).

To address whether improved MEK inhibition can lead to therapeutic efficacy in UM, we utilized the GEMMs to perform *in vivo* trametinib treatment. We needed relevant control tumors that formed nodules of a similar size and were responsive to trametinib treatment. We observed Bap1^KO^ also accelerated BRaf^V600E^-driven tumors to form nodules amenable for treatment (unpublished data). We subcutaneously grafted skin melanomas, isolated from *BRaf^V600E^;Bap1^KO^* and *GNA11^Q209L^;Bap1^KO^* mice, into severe combined immunodeficiency (SCID) mice. The grafts retained features of the *in situ* tumors, where GNA11^Q209L^;Bap1^KO^ tumors retained hyper-pigmentation whereas BRaf^V600E^;Bap1^KO^ tumors were hypopigmented and exhibited elevated MAPK output ([Figures 4A and 4B](#F4){ref-type="fig"}). In BRaf^V600E^ Bap1^KO^ tumors, short-term trametinib treatment decreased proliferation and MAPK output, whereas in GNA11^Q209L^ Bap1^KO^ tumors, the effects were modest ([Figures 4A--4C](#F4){ref-type="fig"}). Long-term treatment resulted in initial tumor shrinkage followed by stabilization in BRaf^V600E^ Bap1^KO^ tumors ([Figure 4D](#F4){ref-type="fig"}). However, GNA11^Q209L^ Bap1^KO^ tumors were resistant to trametinib treatment ([Figure 4D](#F4){ref-type="fig"}). To determine if relative resistance to trametinib treatment was more generalized, we treated human BRAF^V600E^ CM and Gα~q/11~ mutant UM cell lines with a clinically achievable concentration of trametinib (10 nM) ([@R25]). Trametinib sustainably inhibited MAPK in CM cells. In UM cells, MEK phosphorylation was stable or increased over time and ERK phosphorylation was variably inhibited but rebounded by 24 hr ([Figure 4E](#F4){ref-type="fig"}). This is consistent with known hypersensitivity of BRAF^V600E^ melanoma to MEK inhibition ([@R41]). Together, activating mutations in the Gα~11/q~ pathway exhibit *in vivo* and *in vitro* resistance to MEK inhibition. This highlights the need for novel therapeutic targets in UM.

Cross-Species Analysis Shows Gα~11/q~-Driven Tumors Enforce a Melanocyte Lineage Program and Express High Levels of RASGRP3 {#S7}
---------------------------------------------------------------------------------------------------------------------------

To identify critical nodes in Gα~11/q~-mediated tumorigenesis, we utilized a cross-species transcriptome analysis approach of human and murine melanoma. We sought to generate a transcriptional signature of Gα~11~-driven GEMM melanoma. We generated GEMM Gα~11~ and BRaf signatures with differentially expressed genes between GNA11^Q209L^ Bap1^KO^ and BRaf^V600E^ Bap1^KO^ melanomas (\>3-fold, false discovery rate \[FDR\] \< 0.01). In human melanoma, we combined and curated TCGA skin CM (SKCM) ([@R7]) and UM datasets, and we compared tumors with hotspot mutations in Gα~11/q~ (74/80 UM and 5/333 SKCM) with BRAF^V600E^ (0/80 UM and 121/333 SKCM). GSEA using the GEMM signatures on the TCGA transcriptomes showed significant enrichment of the Gα~11~ and Braf signatures in human Gα~11/q~-mutated and BRAF^V600E^ tumors, respectively ([Figure 5A](#F5){ref-type="fig"}). Therefore, the oncogenic signaling driver, in addition to the location of the tumor, contributes to the oncogenic transcriptome. Functional annotation of the leading edge Gα~11/q~ signature genes showed upregulation of pigmentation and melanocyte differentiation pathways ([Figures 5B--5D](#F5){ref-type="fig"}), consistent with the observation of highly pigmented melanomas in the GNA11^Q209L^ GEMM ([Figures 1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"}, and [4](#F4){ref-type="fig"}). This is also consistent with the clinicopathological observations that metastatic UMs retain greater pigmentation than CMs ([@R39]) and with our previous observation that *CYSLTR2^L129Q^* enforces a melanocyte lineage ([@R35]).

Further examination of top-ranked genes identified *RASGRP3* as highly expressed in both Gα~11/q~-mutated human and GEMM melanomas ([Figures 5E and 5F](#F5){ref-type="fig"}). Pan-cancer analysis of RNA-seq datasets from TCGA ([Figure 5E](#F5){ref-type="fig"}) and Affymetrix U133Plus2 datasets curated by gene expression across normal and tumor tissue (GENT) ([Figure S6](#SD1){ref-type="supplementary-material"}) showed *RASGRP3* is expressed at significantly higher levels in UMs than in CMs and other cancer types. Notably, all TCGA UMs expressed high *RASGRP3*, and the five TCGA SKCMs with the highest *RASGRP3* expression harbored either *GNAQ* or *GNA11* mutations and either BAP1 loss (mutation or monosomy 3) or *SF3B1* mutations, suggesting they may be malignant blue nevi ([@R21]) ([Figure 5E](#F5){ref-type="fig"}, circled). *RASGRP3* encodes Ras guanyl-releasing protein 3 (RasGRP3), a GEF that promotes the release of GDP-bound Ras in order to bind GTP, yielding active Ras (Ras-GTP) ([@R37]). RasGRP3 activation is dependent on both DAG binding and phosphorylation on Thr 133 by protein kinase C (PKC) ([@R1]; [@R48]). Together, these signaling events place the activation of RasGRP3 downstream of UM-activating mutations (*CYSLTR2*, *GNAQ*, *GNA11*, and *PLCB4*), and they suggest RasGRP3 may be a key signaling node that can integrate the UM-activating mutations into the MAPK pathway.

To determine if RasGRP3 expression is retained in cell lines, we screened a panel of UM and CM cells, and we found RasGRP3 to be expressed exclusively in UM cells ([Figure 5G](#F5){ref-type="fig"}).

RasGRP3 Is Required for Ras-MAPK Activation and Growth in UM Cells {#S8}
------------------------------------------------------------------

To determine if RasGRP3 is required for Gα~11/q~-mediated activation of the MAPK pathway and for growth in UM, we generated two short hairpin RNAs (shRNAs) to mediate knockdown of *RASGRP3* (shRasGRP3-1 and shRasGRP3-2) and a control (shSCR). Depletion of RasGRP3 significantly reduced cell proliferation in *GNA11* or *GNAQ* mutant cells ([Figures 6A](#F6){ref-type="fig"} and [S7A](#SD1){ref-type="supplementary-material"}). In contrast, knockdown of RasGRP3 in CM cells did not ([Figures 6B](#F6){ref-type="fig"} and [S7A](#SD1){ref-type="supplementary-material"}).

We next sought to characterize the response of RasGRP3 depletion in the context of Ras activation and subsequent downstream MAPK signaling. We stably expressed two doxycycline (dox)-inducible RasGRP3 shRNAs (dox-shRasGRP3-1 and dox-shRasGRP3-2) and a dox-inducible control (dox-shSCR) in the panel of UM and CM cells. Depletion of RasGRP3 with dox significantly reduced the proportion of Ras-GTP and phosphorylation of ERK1/2 and P90^RSK^ in UM cells ([Figure 6C](#F6){ref-type="fig"}). Consistent with the cellular growth data, there was no change in Ras activation or MAPK signaling upon depletion of RasGRP3 in CM cells ([Figure 6C](#F6){ref-type="fig"}).

To elucidate the requirement of the Ras GEF activity of RasGRP3, we examined if ectopic expression of KRAS^G12V^ could rescue the proliferation and MAPK signaling in three UM cell lines depleted of RasGRP3. We performed growth competition assays in which we first generated cells where 20%--50% expressed KRAS^G12V^-IRES-GFP and empty vector at low MOI. We next infected these cells with shSCR or shRasGRP3, and we tracked the percentage of GFP-positive cells over time using fluorescence-activated cell sorting (FACS). The percentage of empty vector-expressing GFP-positive cells remained stable over time regardless of RasGRP3 depletion in both CM and UM cells ([Figure S7B](#SD1){ref-type="supplementary-material"}). In contrast, the percentage of KRAS^G12V^-expressing GFP-positive cells increased after RasGRP3 depletion compared to shSCR in all three UM lines ([Figure 6D](#F6){ref-type="fig"}), indicating KRAS^G12V^ conveys a growth advantage specifically after RasGRP3 depletion. Expression of KRAS^G12V^ rescued the reduction in ERK phosphorylation observed upon depletion of RasGRP3 ([Figure 6E](#F6){ref-type="fig"}). Ectopic expression of KRAS^G12V^ in a CM cell line (A375) provided no changes in proliferation or ERK phosphorylation ([Figures 6D and 6E](#F6){ref-type="fig"}). Therefore, UM cells require RasGRP3 for Ras activation and cellular proliferation.

RasGRP3 Is Required for Gα~11/q~-Mediated Growth {#S9}
------------------------------------------------

Human UM cells harboring Gα~11/q~ mutations selectively require RasGRP3 for growth and MAPK activation, suggesting Gα~11/q~-mediated oncogenesis might require RasGRP3. To explore this hypothesis, we determined the requirement of RasGRP3 in an immortalized mouse melanocytic cell line, melan-a. Melan-a cells require phorbol esters, such as the DAG analog TPA (12-O-tetradecanoylphorbol-13-acetate), that can activate PKC for growth, and they can become TPA independent upon the expression of oncogenic mutations ([@R45]). We transduced melan-a cells with GNAQ^Q209L^, BRAF^V600E^, and KRAS^G12V^, and we cultured the cells in the absence of TPA to establish oncogene-dependent growth. At baseline, melan-a cells with TPA-dependent growth expressed endogenous Rasgrp3. While GNAQ^Q209L^-dependent cells retained Rasgrp3, BRAF^V600E^-and KRAS^G12V^-dependent cells lost Rasgrp3 ([Figure S7C](#SD1){ref-type="supplementary-material"}). BRAF^V600E^- and KRAS^G12V^-dependent cells lost pigmentation and expression of melanocyte lineage proteins, while GNAQ^Q209L^-dependent cells retained pigmentation and melanocyte lineage proteins ([Figure S7C](#SD1){ref-type="supplementary-material"}). Re-introduction of TPA to the media of BRAF^V600E^- and KRAS^G12V^-dependent cells failed to re-establish Rasgrp3 expression ([Figure S7D](#SD1){ref-type="supplementary-material"}). The difference in melanocyte lineage commitment between Gα~11/q~ and RAS/RAF-driven transformed melanocytes is consistent with observations in our GEMMs and patient tumors.

To determine the potential role of RasGRP3 in Gα~11/q~-, BRAF-, and KRAS-mediated tumorigenesis, we performed shRNA-mediated knockdown of *Rasgrp3* (shRasgrp3-1 and shRasgrp3-2). Knockdown of Rasgrp3 significantly reduced cell growth in GNAQ^Q209L^-dependent, but not in BRAF^V600E^- or KRAS^G12V^-dependent, melan-a cells ([Figures 7A](#F7){ref-type="fig"} and [S7E](#SD1){ref-type="supplementary-material"}). Depletion of Rasgrp3 in GNAQ^Q209L^ melan-a cells reduced Ras-GTP and the phosphorylation of ERK and P90^RSK^ ([Figure 7B](#F7){ref-type="fig"}). Therefore, RasGRP3 is specifically required for Gα~11/q~-mediated oncogenic growth.

DISCUSSION {#S10}
==========

UMs, LMNs, and blue nevi harbor activating mutations along the CYSLTR2-Gα~11/q~-PLCβ pathway, and they can have mutually exclusive cooperating mutations in *BAP1*, *SF3B1*, and *EIF1AX* that convey poor, intermediate, and favorable risk, respectively ([@R13]; [@R19]; [@R30]). This distinct molecular profile is observed in a small subset of CMs and \~10% of mucosal melanomas ([@R40]). Pathologically, UMs are characterized by their retention of the melanocyte lineage program, including pigmentation ([@R39]).

No proven effective therapies exist for UM. As with Ras, it is difficult to target G-proteins with competitive inhibitors to the nucleotide-binding site due to the high cellular concentrations of GTP. Since Gα~11/q~ signaling activates PKC and the MAPK pathway, via PLCβ, many groups have studied the role of PKC and MAPK in UM. Cells with Gα~11/q~ mutations were modestly sensitive to MEK inhibition and combination treatment of PKC and MEK inhibitors ([@R9]). Unfortunately, PKC targeting is limited by toxicity, and a completed phase 3 trial with selumetinib showed no clinical benefit ([@R29]). In addition to PLCβ, Gα~q~ directly interacts with the Trio family of Rho-GEFs (Trio, p63-RhoGEF, and Kalirin) to activate Rac and Rho and downstream YAP, and this pathway may represent a therapeutic target ([@R16]; [@R47]). Another promising target is ARF6, a GTPase involved in vesicle trafficking and required for proper shuttling of activated Gα~q~ to cytoplasmic vesicles, where downstream signaling to both PLCβ and Rho were localized ([@R46]). In addition to Gα~11/q~ signaling, another therapeutic strategy is targeting the melanocyte lineage. IMCgp100 is a bispecific antibody that binds gp100 (*PMEL*) on tumor cells and CD3 on T cells ([@R8], J. Stem Cell Res. Ther., abstract). A phase 1 trial in melanoma showed a disease control rate of 21% and 57% in CM and UM, respectively, and an expanded study in UM showed a similar disease control rate with some durable responses ([@R24]).

Here we sought to generate a clinically relevant GEMM of aggressive Gα~11~-driven melanoma, combining *GNA11^Q209L^* and BAP1 loss, and we compared it to an isogenic *BRaf^V600E^* model to identify Gα~11~-driven phenotypes and vulnerabilities. We found GNA11^Q209L^ drove neoplastic growth in cutaneous and many non-cutaneous sites whereas BRaf^V600E^ only promotes CM. While the lung and lymph nodes are the preferential sites of metastasis in the *Tyr*-*CreER^T2^;BRaf^CA/+^;Pten^flox/flox^* mouse ([@R12]) and in a transgenic mouse of *Tyr*-driven SV40 T-antigen ([@R6]), one limitation in our mouse model was the inability to specifically activate *GNA11^Q209L^* in defined melanocytic subsets, and this hampers the ability to definitively assign metastasis ([@R18]; [@R28]).

GNA11^Q209L^-driven tumors were highly pigmented compared to BRaf^V600E^, consistent with clinical observation that Gα~11/q~-driven primary blue nevi, UM, and UM metastases retain pigmentation ([@R15]; [@R39]). Therefore, Gα~q/11~ signaling drives lineage commitment, and targeting the lineage, such as IMCgp100, is a promising therapeutic strategy ([@R8], J. Stem Cell Res. Ther., abstract). Bap1 loss in our GEMM accelerated skin melanoma growth, consistent with the clinical observation that BAP1 loss is found in transformed, but not benign, blue nevi ([@R21]). Yet, there was no significant change of uveal pathology, highlighting a limitation of our model.

Cross-species comparison between representative GEMM models with human disease can identify critical mediators of tumorigenesis ([@R27]). By cross-referencing the RNA-seq data from the GEMM and human disease data, we identified a Ras-GEF, RasGRP3, as a required signaling node for UM. Consistent with a recently published study ([@R10]), we observed RasGRP3 is highly upregulated in UM and is required for proliferation. We additionally showed engineered cells driven by mutant Gα~11/q~ specifically require RasGRP3 for Ras activation and growth. *RASGPR3* expression is tissue specific and, among cancers, constrained to Gα~11/q~-driven melanomas, leukemias, and lymphomas, suggesting RasGRP3 is a specific vulnerability in Gα~11/q~-driven tumors and potentially a therapeutic target. The interaction between G-proteins and their GEFs is a viable drug target, as exemplified by the antibiotic brefeldin A, which blocks interaction between ARF1 and its GEF Sec7 ([@R36]), and RasGRP3 may be similarly targeted.

EXPERIMENTAL PROCEDURES {#S11}
=======================

Further details and an outline of the resources used in this work can be found in the [Supplemental Experimental Procedures](#SD1){ref-type="supplementary-material"}.

Mouse Experiments {#S12}
-----------------

All animal studies were performed in accordance with the MSKCC IACUC (11-12-029). For GEMM studies, three cohorts of mice, *Tyr-CreER^T2^;GNA11^Q209L^*, *Tyr-CreER^T2^;GNA11^Q209L^;Bap1^lox/lox^*, and *Tyr-CreER^T2^;BRaf^CA/+^;Bap1^lox/lox^*, were administered with intraperitoneal tamoxifen at 4 weeks of age with no regard to the sex of the animals, and histology was similar between males and females. Mice developed tumors *in situ* after tamoxifen injection. Mice were euthanized in response but not limited to the following: tumors larger than 1 cm^3^, tumor ulceration, tumors located too close to the trunk of the mice to impede movement and blood flow, and tumor burden, and time of euthanization was used for Kaplan-Meier survival analysis. For allograft studies, GEMM-derived tumors were grafted into 6- to 8-week-old female CB17-SCID mice and treated with vehicle or trametinib via oral gavage.

Histology, Immunohistochemistry, and Immunofluorescence {#S13}
-------------------------------------------------------

All tissues were fixed at 4°C overnight in 4% paraformaldehyde. Tissue processing, embedding, sectioning, H&E staining, and H&E staining with melanin bleaching were performed by Histoserv. Skull sections were performed following decalcification.

RNA-Seq {#S14}
-------

Total RNA was extracted from fresh-frozen tissue or cell lines using QIAGEN's RNeasy Mini Kit. The isolated RNA was processed for RNA-seq by the Integrated Genomics Core Facility at MSKCC.

Cell Lines {#S15}
----------

Melan-a cells were provided by D. Bennett ([@R5]); MEL202, MEL270, OMM1.3, COLO800, UPMM3, A375, and A2058 cells were submitted for short tandem repeat (STR) profiling and MSK-IMPACT (integration mutation profiling of actionable cancer targets) for mutational status at MSKCC to confirm their authenticity.

Statistics {#S16}
----------

Boxplots represent 25th and 75th percentiles with midline indicating the median; whiskers extend to the lowest/highest value within 1.5 times the inter-quartile range. Outliers are shown as dots. Comparisons for growth curves and xenograft experiments between two groups were performed using a two-tailed parametric unpaired t test. All statistics were performed using GraphPad Prism 6.0 software.
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![Melanocyte-Specific *GNA11^Q209L^* Expression Induces Cutaneous and UM\
(A and B) H&E of skin (A) and eye (B) from *Tyr-CreER^T2^*-negative control mice 3 months post-induction.\
(C and D) H&E of skin from GNA11^Q209L^ mice 3 months (C) or 6 months (D) post-induction.\
(E and F) H&E of eyes from GNA11^Q209L^ mice 3 months (E) or 6 months (F) post-induction.\
(G) H&E (i), H&E with melanin bleaching (ii), MITF immunohistochemistry (IHC) using diaminobenzidine (DAB) (brown) (iii), and melanoma cocktail IHC using red chromogen (red) (iv) from a GNA11^Q209L^ mouse 6 months post-induction. High-magnification insets of top panels are shown in bottom panel.\
(H) H&E of a selected eye (i) with melanocytic perineural invasion of the optic nerve (ii).\
See also [Figures S1 and S2](#SD1){ref-type="supplementary-material"}.](nihms949230f1){#F1}

![Melanocyte-Specific *GNA11^Q209L^* Expression Induces Leptomeningeal Melanocytic Neoplasia and Possible Metastasis\
(A) H&E of coronal skull sections (left), magnified images of regions showing melanocytic neoplasia in the (i) choroid plexus of the third ventricle (i), leptomeninges of brain base surrounding cranial nerve roots (ii and iii), longitudinal fissure and ependyma of the third ventricle olfactory bulb (iv and v). Arrow indicates the harderian gland.\
(B) H&E of heart and lung. Arrows indicate lesions.\
(C) Magnification of heart in (B) showing melanoma in the tricuspid valve, right atrial wall, and interventricular septum indicated by box and gray arrow in (B).\
(D and E) Magnification of a selected melanocytic lesion (D) in the lung indicated by box and arrow in (B) and with melanin bleaching (E).\
(F and G) H&E (F) and MITF IHC (G) of axillary lymph node melanocytic lesion (G, ii).\
See also [Figure S3](#SD1){ref-type="supplementary-material"}.](nihms949230f2){#F2}

![Bap1 Loss Promotes Aggressive Melanomas\
(A) Photographs of GNA11^Q209L^ (left) and GNA11^Q209L^ Bap1^KO^ (right) mice 3 months post-induction.\
(B and C) H&E of eyes from GNA11^Q209L^ (B) and GNA11^Q209L^ Bap1^KO^ (C) mice 12 months post-induction.\
(D) Kaplan-Meier curve comparing the survival percentage of GNA11^Q209L^ (blue) or GNA11^Q209L^ Bap1^lox/+^ (green) to GNA11^Q209L^ Bap1^KO^ mice (red). p = 0.0013.\
(E and F) Photograph of large invasive melanoma from the tail dermis (E) and H&E (F) from a GNA11^Q209L^ Bap1^KO^ mouse 12 months post-induction.\
(G) H&E of an invasive melanoma from the dermis of the ear from a GNA11^Q209L^ Bap1^KO^ mouse 12 months post-induction.\
(H) Ki-67 IHC in GNA11^Q209L^ (top) and GNA11^Q209L^ Bap1^KO^ (bottom) cutaneous tumors.\
(I) Quantification of Ki-67-positive cells. Scatter-dot plot: each dot represents the quantification of one field. Error bars represent means ± SEM. p \< 0.0001.\
(J) GSEA plot using a gene set comprised of genes upregulated in mice (Mouse_Bap1KO_UP) on a profile of genes ranked by correlation to *BAP1* expression in the UM TCGA dataset.\
(K) GO and SP pathways from leading edge genes (red; J) upregulated in GNA11^Q209L^ Bap1^KO^ tumors and negatively correlated with *BAP1* expression in TCGA UM.\
(L) GSEA plot using Mouse_Bap1KO_UP gene set (as in J) on a profile of genes ranked by change in UMMP3 cells upon BAP1 wild-type (WT) restoration.\
(M) GO and SP pathways from leading edge genes (red; L) upregulated in GNA11^Q209L^ Bap1^KO^ tumors and downregulated upon BAP1 restoration in UMMP3 cells.\
See also [Figures S4 and S5](#SD1){ref-type="supplementary-material"} and [Table S1](#SD2){ref-type="supplementary-material"}.](nihms949230f3){#F3}

![Reduced MEK Sensitivity in Gα~11/q~-Driven Tumors\
(A) H&E and Ki-67 IHC of GNA11^Q209L^ Bap1^KO^ and BRAF^V600E^ Bap1^KO^ tumors treated with trametinib or vehicle.\
(B) Immunoblots for MAPK in explanted control and trametinib-treated GNA11^Q209L^ Bap1^KO^ and BRAF^V600E^ Bap1^KO^ tumors.\
(C) Quantification of Ki67 in explanted control and trametinib-treated GNA11^Q209L^ Bap1^KO^ and BRAF^V600E^ Bap1^KO^ tumors, shown as Tukey box-and-whisker plots. Outliers are shown as dots. p \< 0.0001.\
(D) Tumor growth of grafted GNA11^Q209L^Bap1^KO^ or BRAF^V600E^ Bap1^KO^ tumors in SCID mice with treatment as indicated. n = tumors per group. Error bars, SEM. p \< 0.001 for BRAF^V600E^ Bap1^KO^ treatment.\
(E) Immunoblot of Gα~11/q~ mutant UM and BRAF mutant CM cell lines treated with 10 nM trametinib.](nihms949230f4){#F4}

![Gα~11/q~-Driven Tumors Enforce a Melanocyte Lineage Program and Express High Levels of *RASGRP3*\
(A) GSEA profile using the GEMM gene sets (Mouse BRaf UP and Mouse Gα~11/q~ UP) on a profile ranked by expression difference between Gα~11/q~ mutant and BRAF^V600E^ mutant melanomas in the combined TCGA SKCM and UM datasets.\
(B) GO and SP pathways from leading edge genes (left; red; A) overexpressed in Gα~11/q~ GEMM tumors and human Gα~11/q~ mutant.\
(C and D) Melanocyte-lineage genes shown as Tukey box-and-whisker plots from BRaf^V600E^ and GNA11^Q209L^ GEMM (C) and TCGA SKCM melanomas (D). Outliers are shown as dots. p \< 10^−6^.\
(E) *RASGRP3* expression from pan-cancer TCGA shown as Tukey box-and-whisker plots. Outliers are shown as red dots. UM is highlighted in red. SKCM is highlighted in blue. Outliers with *GNAQ*, *GNA11*, *BAP1*, and *SF3B1* mutations are circled and detailed.\
(F) RasGRP3 expression shown as Tukey box-and-whisker plots from GEMM tumors. p \< 10^−6^.\
(G) Immunoblot of RASGRP3 in human UM and CM cell lines.\
See also [Figure S6](#SD1){ref-type="supplementary-material"}.](nihms949230f5){#F5}

![RASGRP3 Is Required for Growth and ras Activation in UM Cells\
(A and B) Growth curves of UM (A) or CM (B) cells with shSCR, shRASGRP3-1, or shRASGRP3-2, shown as relative luminescence units (RLUs). Error bars, means ± SEM from six technical replicates. p \< 0.001 (A), p = not significant (ns), and p = 0.016 (B).\
(C) Immunoblots of RASGRP3 and MAPK pathway. UM and CM cells stably expressing dox-shSCR, dox-shRASGRP3-1, or dox-shRASGRP3-2 in the presence of dox are shown.\
(D) Percentage GFP-positive cells over time expressing KRAS^G12V^-IRES-GFP with shSCR, shRASGRP3-1, or shRASGRP3-2. Change of percentage GFP-positive indicates relative growth of KRAS^G12V^-expressing cells to non-expressing cells.\
(E) Immunoblot of bulk cells (D) against the indicated proteins.\
See also [Figure S7](#SD1){ref-type="supplementary-material"}.](nihms949230f6){#F6}

![Rasgrp3 Is Required for Gα~11/q~-Mediated Growth and MAPK Activation in Melan-a Cells\
(A) Growth curves of GNAQ^Q209L^, BRAF^V600E^, or KRAS^G12V^ melan-a cells, grown in the absence of TPA and expressing shSCR, shRasgrp3-1, or shRasgrp3-2, shown as RLUs. Error bars, means ± SEM from six technical replicates. p \< 0.001 (GNAQ^Q209L^) and p = ns (BRAF^V600E^ and KRAS^G12V^) for reduction in growth.\
(B) Immunoblots of Rasgrp3 and MAPK pathway following Rasgrp3 depletion.\
See also [Figure S7](#SD1){ref-type="supplementary-material"}.](nihms949230f7){#F7}

###### Highlights

-   GNA11 Q209L mouse model induces uveal, cutaneous, and leptomeningeal melanoma

-   Loss of Bap1 promotes aggressive melanomas

-   RasGRP3 links GNA11/GNAQ activation to RAS activation

-   RasGRP3 is required for GNA11/GNAQ-driven tumorigenesis

[^1]: Lead Contact
